Background: Metabolic syndrome (MetS) is characterized by chronic inflammation, oxidative stress, and mitochondrial dysfunction. MetS is associated with increased intestinal permeability and dysbiosis. The objective of this study was to investigate the effects of peanut shell extract (PSE) and luteolin (LUT) on the kidneys, colon, and ileum in a MetS-like murine model. Methods: Thirty-six male Slc6a14^y/− mice were divided into four groups: low-fat diet (LFD), high-fat diet (HFD), HFD + 200 mg PSE/kg BW (PSE, p.o.), and HFD + 100 mg LUT/kg BW (LUT, p.o.) for 4 months. Outcome measures included glucose homeostasis, intestinal permeability, gut microbiome composition, and mRNA gene expression of mitochondrial homeostasis and inflammation/oxidative stress in the kidneys, colon, and ileum. Results: HFD resulted in glucose dysregulation with hyperglycemia and insulin resistance. PSE and LUT improved insulin tolerance and beta-cell function. PSE and LUT mitigated HFD-increased serum lipopolysaccharide-binding protein concentration. Perturbations in the gut microbiome were associated with HFD, and PSE or LUT reversed some of these changes. Specifically, Phocaeicola vulgatus was depleted by HFD and reverted by PSE or LUT. Relative to the LFD group, the HFD group (1) upregulated mitochondrial fusion (MFN1, MFN2, OPA1), mitophagy (TLR4, PINK1, LC3B), and inflammation (NFκB, TNFα, IL6), and (2) downregulated mitochondrial fission (FIS1, DRP1), biosynthesis (PGC1α, NRF1, NRF2, TFAM), electron transport chain (complex I), and antioxidant enzyme (SOD1) in the kidneys, colon, and ileum. Conclusions: PSE and LUT reversed such HFD-induced changes in the aforementioned gene expression levels.

Background/Objective: There is strong evidence that the tripartite interaction between glucose homeostasis, gut microbiota, and the host immune system plays a critical role in the pathophysiology of type 2 diabetes mellitus (T2DM). We reported previously that peanut shell extract (PSE) improves mitochondrial function in db/db mice by suppressing oxidative stress and inflammation in the liver, brain, and white adipose tissue. This study evaluated the impacts of PSE supplementation on glucose homeostasis, liver histology, intestinal microbiome composition, and the innate immune response in diabetic mice. Methods: Fourteen db/db mice were randomly assigned to a diabetic group (DM, AIN-93G diet) and a PSE group (1% wt/wt PSE in the AIN-93G diet) for 5 weeks. Six C57BL/6J mice received the AIN-93G diet for 5 weeks (control group). Parameters of glucose homeostasis included serum insulin, HOMA-IR, HOMA-B, and the analysis of pancreatic tissues for insulin and glucagon. We assessed the innate immune response in the colon and liver using a microarray. Gut microbiome composition of cecal contents was analyzed using 16S rRNA gene amplicon sequencing. Results: PSE supplementation improved glucose homeostasis (decreased serum insulin concentration, HOMA-IR, and HOMA-B) and reduced hepatic lipidosis in diabetic mice. PSE supplementation reversed DM-induced shifts in the relative abundance of amplicon sequence variants of Enterorhabdus, Staphylococcus, Anaerotruncus, and Akkermansia. Relative to the DM mice, the PSE group had suppressed gene expression levels of Cd8α, Csf2, and Irf23 and increased expression levels of Tyk2, Myd88, and Gusb in the liver. Conclusions: This study demonstrates that PSE supplementation improves T2DM-associated disorders of diabetic mice, in part due to the suppression of innate immune inflammation.

Diet-induced obesity contributes to chronic inflammation, mitochondrial dysfunction, and progressive kidney injury, while increased dietary acid load may further impair renal homeostasis. In our previous studies, we showed that ammonium hydroxide enhancement (AHE) of dietary protein, prior to incorporation into the complete diet, increases dietary alkalinity and has improved longevity, decreased secretion of adipocytokines, and beneficially affected the microbiome in high-fat diet fed C3H/HeJ mice. However, its effects on renal molecular and structural responses remain unknown. In this study, kidney tissues from male C3H/HeJ mice fed control casein (CC), ammonium hydroxide-enhanced casein (CCN), high-fat casein (HFC), ammonium hydroxide-enhanced high-fat casein (HFCN), high-fat beef (HFB), or ammonium hydroxide-enhanced high-fat beef (HFBN) diets were analyzed using quantitative PCR, Western blotting, and histological morphometry. Results showed that AHE reduced renal inflammatory signaling, evidenced by decreased TLR4, TNFα, Il1-β, IL6, and NFκB expression. Apoptosis-associated signaling was attenuated through reduced Caspase-3 and p53 expressions and increased BCL2 levels. AHE also modulated mitochondrial-associated markers. Increased markers of mitochondrial biogenesis and fusion, and decreased fission-associated markers were observed, along with increased PINK1 expression, while Parkin remained unchanged. In addition, expression levels of the ammonia transporters, RHBG and RHCG, were elevated, indicating altered renal ammonia transporter expression. Histological and morphometric analyses demonstrated AHE-associated changes in tubular areas, while glomerular and Bowman’s capsule areas remained largely unchanged. Collectively, these findings suggest that long-term dietary AHE is associated with alterations in renal inflammatory and apoptotic signaling, mitochondrial-associated pathways, ammonia transporter expression, and renal histomorphometry in male C3H/HeJ mice.

Diabetes mellitus is a complex metabolic disease characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both. In addition to disturbances in glucose metabolism, the disease is accompanied by abnormalities in mitochondrial dysfunction, oxidative stress, lipid and protein metabolism, and chronic inflammation that contribute to progressive tissue injury and the development of vascular complications. Although current pharmacological therapies effectively improve glycemic control, many patients continue to experience disease progression and diabetes-associated complications, highlighting the need for complementary therapeutic strategies that target multiple pathogenic mechanisms. Growing evidence suggests that naturally occurring bioactive compounds may provide such multitarget benefits. Plant-derived polyphenols, medicinal herbs, culinary spices, and functional foods have demonstrated antioxidant, anti-inflammatory, hypoglycemic, hypolipidemic, and insulin-sensitizing properties in experimental and clinical studies. Compounds including curcumin, honey, garlic, fenugreek, cumin, shilajit, and guduchi have been reported to influence several molecular pathways involved in diabetes pathogenesis, including NF-κB-mediated inflammatory signaling, oxidative and endoplasmic reticulum stress, PPARγ activation, advanced glycation end-product formation, and pancreatic β-cell preservation. This review critically examines current evidence regarding the role of natural products in diabetes management, integrating findings from cell-based studies, animal models, and human clinical investigations. Particular emphasis is placed on the interplay between oxidative stress, inflammation, mitochondrial dysfunction, and metabolic regulation, as these interconnected processes represent key drivers of disease progression. In addition to summarizing established mechanisms, the review discusses current limitations, translational challenges, and future research priorities. A deeper understanding of how natural products modulate these pathways may facilitate the development of evidence-based adjunctive strategies to improve long-term metabolic health and reduce the burden of diabetic complications. This narrative review critically synthesizes published peer-reviewed mechanistic, preclinical, and clinical evidence regarding selected natural products and functional foods relevant to diabetes mellitus.

Breast cancer remains a leading cause of cancer-related mortality worldwide, highlighting the need for novel therapeutic strategies that selectively target tumor cells while minimizing systemic toxicity. Dietary ammonium hydroxide enhancement (AHE) has previously been shown to modulate metabolic pathways in animal studies. However, its potential as a localized anticancer therapy has not been investigated. In the present study, we evaluated the antitumor efficacy and systemic safety of NH₄OH using complementary in vitro and orthotopic breast cancer xenograft models. MDA-MB-231 breast cancer cells and non-tumorigenic MCF10A mammary epithelial cells were treated with increasing concentrations of NH₄OH (2.5–225 µM) to assess dose-dependent effects on cell proliferation, viability, and apoptosis. Following this, MDA-MB-231 cells were orthotopically xenografted into female athymic nude mice and treated by intratumoral injection with NH₄OH using a stepwise dose-escalation regimen (0.01%, 0.1%, and 0.5%; total volume of 20 μL per tumor divided between two injection sites) or phosphate-buffered saline (PBS). Differences between treatment groups of mammary tumors and kidney tissues were analyzed molecularly and histologically. NH₄OH significantly suppressed MDA-MB-231 cell growth and metabolic activity, with minimal effects on MCF10A cells, and induced apoptosis in MDA-MB-231 cells without detectable apoptotic induction in MCF10A cells. In vivo, although tumor volume only showed a non-significant downward trend, histological and molecular analyses demonstrated substantial alterations in tumor biology. NH₄OH treatment induced molecular changes consistent with an antitumor response, including increased Caspase-3 and p53 expression, reduced BCL2 and Ki-67 expression, and attenuation of TNFα, IL-6, and TLR4 inflammatory signaling. Furthermore, the tumor architecture in T-NH tumors displayed increased pale eosinophilic regions and reduced cellular density, suggestive of treatment-associated tumor tissue disruption. Histological analysis of kidney tissue showed no evidence of overt renal toxicity. Indeed, localized NH₄OH administration was associated with reduced renal inflammatory and apoptotic signaling, preserved renal morphology, and increased expression of the ammonia transporters RHBG and RHCG. Cross-sectional morphometric measurements showed decreased area for the distal convoluted tubules in NH₄OH-treated samples. Although this initial preclinical study was limited by a relatively small sample size, further studies are warranted to validate these findings and define the molecular mechanisms underlying NH₄OH-mediated antitumor activity. Collectively, these findings suggest that intratumoral NH₄OH modulates tumor metabolic, inflammatory, and apoptotic pathways associated with a less aggressive tumor phenotype while showing no overt molecular or histological evidence of renal injury, supporting further investigation as a localized metabolic intervention targeting molecular and histological drivers of breast cancer progression.